Translational CRO Vivia Biotech specializes in preclinical and translational drug screening using patient samples, offering physiologically relevant models to improve predictability of clinical outcomes. This presents a sales angle for partners seeking higher translational success rates and data-driven go/no-go decisions.

Industry Experience With over 15 years of expertise and collaborations with more than 100 pharma and biotech companies, Vivia Biotech demonstrates a proven track record and broad network that can help potential clients de-risk early development and access diverse therapeutic insights.

ClientRetention A client return rate exceeding 80% indicates strong satisfaction and reliability. This suggests a compelling value proposition for repeat collaborations, multi-project partnerships, and long-term outsourcing arrangements.

Decision Enablement The company emphasizes optimizing candidate selection by linking functional assays with molecular biomarkers, enabling faster go/no-go decisions and potentially reducing time and cost in regulatory submissions.

Expansion Opportunities Vivia’s capabilities span hematological malignancies, solid tumors, and autoimmune diseases, offering cross-therapy opportunities for pharmaceutical partners seeking breadth in preclinical screening, companion diagnostics, or biomarker-driven trial design.